Provention Bio, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Provention Bio, Inc. (NASDAQ: PRVB) securities between November 2, 2020 and April 8, 2021.
According to the Provention Bio lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application (“BLA”) was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA’s approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
“Provention Bio, Inc.”
If you suffered a loss in Provention Bio you have until July 20, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.